Business Context and Reporting Period
This Form 8-K, dated June 28, 2018, reports that Akebia Therapeutics, Inc. (Akebia) entered into a definitive merger agreement to acquire Keryx Biopharmaceuticals, Inc. (Keryx). Both companies are biopharmaceutical firms focused on therapies for kidney disease. The transaction is structured as a stock-for-stock merger where Keryx will become a wholly-owned subsidiary of Akebia.
Key Financial Metrics and Transaction Terms
The filing details the terms of the merger rather than historical financial performance metrics such as revenue or cash flow.
- Exchange Ratio: Each outstanding Keryx share will be converted into 0.37433 shares of Akebia common stock.
- Termination Fee: A termination fee of $22 million may be payable by either party under specified circumstances.
- Debt Conversion: Baupost Group Securities, L.L.C., holder of Keryx's Zero Coupon Convertible Senior Notes due 2021, agreed to convert the notes into 35,582,335 shares of Keryx common stock immediately prior to the merger effective time.
- Additional Shares: Baupost will receive an additional 4,000,000 shares of Keryx common stock as part of the conversion agreement.
- Liquidity and Capital: The filing does not provide specific cash balance, debt, or liquidity figures for either company.
Material Changes and Governance
The primary material change is the proposed consolidation of the two entities. Key governance changes include:
- Board Composition: The post-merger Akebia board will expand to nine directors: four continuing Akebia directors, four Keryx designees, and one additional director designated by Keryx to serve as chairperson.
- Executive Leadership: John Butler is required to continue as Chief Executive Officer of Akebia post-merger.
- Shareholder Support: Baupost, owning approximately 21.4% of Keryx, has entered a voting agreement to support the merger.
Guidance, Outlook, and Risks
Outlook and Timing: The parties expect the merger to be completed by the end of 2018. Management anticipates benefits including efficiencies, cost savings, tax benefits, enhanced revenues, and cash flow, though no specific numerical guidance is provided in this filing.
Conditions to Closing: The transaction is subject to customary conditions, including:
- Approval by a majority of Akebia and Keryx shareholders.
- NASDAQ listing approval for the new shares.
- Expiration of the Hart-Scott-Rodino waiting period.
- Conversion of Keryx's convertible notes by Baupost.
- Absence of material adverse effects on either company.
Risks: Significant risks include the failure to obtain shareholder or regulatory approvals, unexpected costs or liabilities, disruption of operations, and the inability to realize anticipated synergies.
Investor Verification Checklist
- Verify the final vote results from Akebia and Keryx shareholders regarding the merger approval.
- Confirm the successful conversion of Keryx's convertible notes by Baupost as a condition precedent.
- Review the upcoming joint proxy statement/prospectus for detailed financial projections and risk factors.
- Monitor regulatory filings for any antitrust or other governmental conditions imposed on the transaction.
- Check for any competing transaction proposals that might trigger a fiduciary out clause.